GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Huahai Pharmaceutical Co Ltd (SHSE:600521) » Definitions » Capex-to-Operating-Income

Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Capex-to-Operating-Income : 1.00 (As of Mar. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Zhejiang Huahai Pharmaceutical Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Zhejiang Huahai Pharmaceutical Co's Capital Expenditure for the three months ended in Mar. 2024 was ¥-478.29 Mil. Its Operating Income for the three months ended in Mar. 2024 was ¥476.79 Mil.

Hence, Zhejiang Huahai Pharmaceutical Co's Capex-to-Operating-Income for the three months ended in Mar. 2024 was 1.00.


Zhejiang Huahai Pharmaceutical Co Capex-to-Operating-Income Historical Data

The historical data trend for Zhejiang Huahai Pharmaceutical Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Huahai Pharmaceutical Co Capex-to-Operating-Income Chart

Zhejiang Huahai Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.71 0.80 3.71 1.34 1.03

Zhejiang Huahai Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.37 0.93 1.05 0.81 1.00

Competitive Comparison of Zhejiang Huahai Pharmaceutical Co's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Huahai Pharmaceutical Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Huahai Pharmaceutical Co's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Huahai Pharmaceutical Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Zhejiang Huahai Pharmaceutical Co's Capex-to-Operating-Income falls into.



Zhejiang Huahai Pharmaceutical Co Capex-to-Operating-Income Calculation

Zhejiang Huahai Pharmaceutical Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1592.387) / 1547.321
=1.03

Zhejiang Huahai Pharmaceutical Co's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-478.288) / 476.793
=1.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Huahai Pharmaceutical Co  (SHSE:600521) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Zhejiang Huahai Pharmaceutical Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Zhejiang Huahai Pharmaceutical Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Business Description

Traded in Other Exchanges
N/A
Address
Economic Development Zone, Xunqiao Town, Linhai, Taizhou, Zhejiang, CHN, 317024
Zhejiang Huahai Pharmaceutical Co Ltd provides formulations, active pharmaceutical ingredients, and intermediates in China and internationally. The company also offers pril products, including captopril, enalapril, and lisinopril.
Executives
Chen Bao Hua Director
Shang Fei senior management
Du Jun Director
Su Yan Director
Chen Dun Yuan senior management
Li Hong Director
Guo Si Jia senior management
Li Min senior management
Xu Bo senior management
Wang Jie senior management
Chen Qi Mao senior management
Zhang Hong senior management
Zhang Mei senior management
Zhu Yong Hua Directors, senior managers
Wang Yi Hua senior management

Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Headlines

No Headlines